Dechra Pharma To Buy Worldwide Rights To Verdinexor For Dogs

Dechra Pharmaceuticals PLC (DPH.L) announced Tuesday that it has agreed terms with Anivive Lifesciences, Inc. to acquire the worldwide rights to verdinexor, a novel treatment of all forms and stages of canine lymphoma in dogs.

Under the deal terms, Dechra will buy the global product rights and a first right of refusal for other species along with the trademark -Laverdia.

Dechra said it will acquire the worldwide marketing rights, the rights to the intellectual property, the marketing authorisations (when granted) and associated regulatory documentation, supply contracts with third parties in relation to the raw material and manufacture of the finished product. No other assets are being transferred to Dechra.

The product, currently sold as LAVERDIA-CA1 in the USA is a novel oral selective inhibitor of nuclear export or SINE drug and the first oral tablet for canine lymphoma.

The drug was conditionally approved by the FDA Center for Veterinary Medicine on January 11, 2021.

Sales of the product in the USA commenced under the conditional approval in July 2021. Full dossier submissions are planned for USA, UK, EU, Brazil, Australia, Japan and Canada.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission or FTC, has sued Walmart for allowing its money transfer services to be used by fraudsters, who fleeced consumers out of hundreds of millions of dollars. The retail giant is alleged to have looked the other way to pocket millions in fees while scammers took advantage of its failure to properly secure the money transfer services offered at Walmart stores. Home improvement retailer Bed Bath & Beyond, Inc. (BBBY) reported on Wednesday a net loss for first quarter that sharply widened from last year, hurt by hefty transient costs related to inventory markdown reserves and port-related supply chain fees. Both adjusted loss per share and net sales missed analysts' expectations. Tesla Inc. laid off about 200 employees in its Autopilot unit as the luxury electric car maker closed down its office in San Mateo, California as part of cost cutting efforts, reports said. The San Mateo office, where employees worked on improving the driver assistance systems, marketed as Autopilot, had about 350 employees before the cut.
Follow RTT